A new study published in the journal of BMC Nephrology revealed rituximab to be an effective and safe steroid sparing medication in individuals with steroid dependent (SD)/frequent relapsing ...

Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

Tailoring rituximab treatment among patients with pemphigus based on the presence of predictors of early relapse reduced relapse rates at 12 months.

A new study suggests that a simple treatment algorithm could significantly reduce disparities in multiple sclerosis care ...

A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS) ...

Results also showed that the more recently people had been treated with the B-cell–depleting therapy rituximab, the lower the levels of immunogenicity that were achieved, and thus protection aga ...

The therapy includes brentuximab vedotin, lenalidomide, and a rituximab product, targeting patients who failed two or more prior systemic therapies. Approval is based on the phase 3 ECHELON-3 ...

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

The FDA has approved Genentech’s subcutaneous version of the cancer drug rituximab, allowing for a more convenient injection lasting minutes, rather than several hours. Branded as Rituxan Hycela ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...